The reduction in clinical endpoints is consistent with previous morbidity and mortality benefits for SGLT-2 inhibitors in T2DM trials [8,9,10] and meta-analyses [1,2,3,4]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.